AR065778A1 - Formas de dosificacion de liberacion retardada/pulsatil de tiempo especifico - Google Patents
Formas de dosificacion de liberacion retardada/pulsatil de tiempo especificoInfo
- Publication number
- AR065778A1 AR065778A1 ARP080101092A ARP080101092A AR065778A1 AR 065778 A1 AR065778 A1 AR 065778A1 AR P080101092 A ARP080101092 A AR P080101092A AR P080101092 A ARP080101092 A AR P080101092A AR 065778 A1 AR065778 A1 AR 065778A1
- Authority
- AR
- Argentina
- Prior art keywords
- starch
- pharmaceutical composition
- composition according
- core
- weight
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- 230000000541 pulsatile effect Effects 0.000 title abstract 2
- 230000003111 delayed effect Effects 0.000 title 1
- 229920002472 Starch Polymers 0.000 abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract 6
- 235000019698 starch Nutrition 0.000 abstract 6
- 239000008107 starch Substances 0.000 abstract 6
- 229940032147 starch Drugs 0.000 abstract 5
- 229920000881 Modified starch Polymers 0.000 abstract 4
- 239000011248 coating agent Substances 0.000 abstract 4
- 238000000576 coating method Methods 0.000 abstract 4
- 235000019426 modified starch Nutrition 0.000 abstract 4
- 239000004480 active ingredient Substances 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 238000007789 sealing Methods 0.000 abstract 3
- 239000004368 Modified starch Substances 0.000 abstract 2
- 229920013820 alkyl cellulose Polymers 0.000 abstract 2
- 229920002678 cellulose Polymers 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 235000010980 cellulose Nutrition 0.000 abstract 2
- 229920001477 hydrophilic polymer Polymers 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- 229920000856 Amylose Polymers 0.000 abstract 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 abstract 1
- 229920002261 Corn starch Polymers 0.000 abstract 1
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 239000000783 alginic acid Substances 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 229960001126 alginic acid Drugs 0.000 abstract 1
- 150000004781 alginic acids Chemical class 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 abstract 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 abstract 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 abstract 1
- 239000008120 corn starch Substances 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000010981 methylcellulose Nutrition 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 229920001592 potato starch Polymers 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 229940071117 starch glycolate Drugs 0.000 abstract 1
- 229920003176 water-insoluble polymer Polymers 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical group CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 abstract 1
- 229960004010 zaleplon Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07104213A EP1970056A1 (en) | 2007-03-15 | 2007-03-15 | Time-specific delayed/pulsatile release dosage forms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065778A1 true AR065778A1 (es) | 2009-07-01 |
Family
ID=38063792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101092A AR065778A1 (es) | 2007-03-15 | 2008-03-14 | Formas de dosificacion de liberacion retardada/pulsatil de tiempo especifico |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100028426A1 (enExample) |
| EP (2) | EP1970056A1 (enExample) |
| JP (1) | JP2010521437A (enExample) |
| KR (1) | KR20090119986A (enExample) |
| CN (1) | CN101636153A (enExample) |
| AR (1) | AR065778A1 (enExample) |
| BR (1) | BRPI0808801A2 (enExample) |
| CA (1) | CA2679210A1 (enExample) |
| MX (1) | MX2009009862A (enExample) |
| RU (1) | RU2452472C2 (enExample) |
| WO (1) | WO2008110577A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2606395T3 (es) | 2008-04-18 | 2017-03-23 | Intec Pharma Ltd. | Administración de fármacos gastrorretentivos para carbidopa/levodopa |
| PL2378883T3 (pl) * | 2008-12-04 | 2016-06-30 | Intec Pharma Ltd | SYSTEM DOSTARCZANIA LEKU ZATRZYMYWANEGO W ŻOŁĄDKU dLA ZALEPLONU |
| EP2375903A4 (en) * | 2008-12-15 | 2012-09-19 | Somnus Therapeutics Inc | METHOD FOR TREATING SILENTNESS |
| CN103816130B (zh) * | 2014-01-22 | 2016-01-20 | 悦康药业集团有限公司 | 一种盐酸二甲双胍缓释片 |
| WO2018011181A1 (en) * | 2016-07-11 | 2018-01-18 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
| IT202000011050A1 (it) * | 2020-05-14 | 2021-11-14 | Mogon Pharmaceuticals Sagl | Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di ingredienti attivi |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4309404A (en) * | 1979-08-09 | 1982-01-05 | American Home Products Corporation | Sustained release pharmaceutical compositions |
| US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
| DE69222006T2 (de) * | 1991-10-30 | 1998-01-22 | Glaxo Group Ltd | Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten |
| AU3949093A (en) * | 1992-03-31 | 1993-11-08 | Benzon Pharma A/S | A pharmaceutical formulation |
| GB9619074D0 (en) * | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
| US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| CO4920215A1 (es) * | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
| EP1064937A1 (en) * | 1999-06-28 | 2001-01-03 | Sanofi-Synthelabo | Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| JP2003507413A (ja) * | 1999-08-26 | 2003-02-25 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | 徐放性鎮静催眠組成物およびそれに関連する方法 |
| WO2001080824A2 (en) * | 2000-04-19 | 2001-11-01 | Eurand America, Inc. | Dual mechanism timed release dosage forms for low dose drugs |
| US6811794B2 (en) * | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| CN1674877A (zh) * | 2002-06-07 | 2005-09-28 | 兰贝克赛实验室有限公司 | 控释的多单位药物释放系统 |
| US20050038042A1 (en) * | 2002-11-15 | 2005-02-17 | Jenet Codd | Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders |
| JP2007509155A (ja) * | 2003-10-21 | 2007-04-12 | アルファーマ インコーポレイテッド | クエチアピンを含有する薬剤 |
| AR052225A1 (es) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones |
| AU2005305459A1 (en) * | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Controlled absorption of statins in the intestine |
| AU2006228525A1 (en) * | 2005-03-28 | 2006-10-05 | Dexcel Pharma Technologies Ltd. | Controlled absorption of statins in the intestine |
| EP1863453A2 (en) * | 2005-03-29 | 2007-12-12 | Evonik Röhm GmbH | Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release |
| US20060280795A1 (en) * | 2005-06-08 | 2006-12-14 | Dexcel Pharma Technologies, Ltd. | Specific time-delayed burst profile delivery system |
-
2007
- 2007-03-15 EP EP07104213A patent/EP1970056A1/en not_active Withdrawn
-
2008
- 2008-03-12 MX MX2009009862A patent/MX2009009862A/es not_active Application Discontinuation
- 2008-03-12 JP JP2009553136A patent/JP2010521437A/ja active Pending
- 2008-03-12 KR KR1020097020728A patent/KR20090119986A/ko not_active Ceased
- 2008-03-12 WO PCT/EP2008/052957 patent/WO2008110577A1/en not_active Ceased
- 2008-03-12 EP EP08717703A patent/EP2120888A1/en not_active Withdrawn
- 2008-03-12 BR BRPI0808801-2A patent/BRPI0808801A2/pt not_active IP Right Cessation
- 2008-03-12 RU RU2009138048/15A patent/RU2452472C2/ru not_active IP Right Cessation
- 2008-03-12 CN CN200880008426A patent/CN101636153A/zh active Pending
- 2008-03-12 CA CA002679210A patent/CA2679210A1/en not_active Abandoned
- 2008-03-12 US US12/450,201 patent/US20100028426A1/en not_active Abandoned
- 2008-03-14 AR ARP080101092A patent/AR065778A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010521437A (ja) | 2010-06-24 |
| CN101636153A (zh) | 2010-01-27 |
| CA2679210A1 (en) | 2008-09-18 |
| MX2009009862A (es) | 2009-12-14 |
| BRPI0808801A2 (pt) | 2014-08-19 |
| RU2452472C2 (ru) | 2012-06-10 |
| US20100028426A1 (en) | 2010-02-04 |
| EP1970056A1 (en) | 2008-09-17 |
| RU2009138048A (ru) | 2011-04-20 |
| EP2120888A1 (en) | 2009-11-25 |
| WO2008110577A1 (en) | 2008-09-18 |
| KR20090119986A (ko) | 2009-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065778A1 (es) | Formas de dosificacion de liberacion retardada/pulsatil de tiempo especifico | |
| JP2011519967A5 (enExample) | ||
| JP2007126470A5 (enExample) | ||
| JP2012502015A5 (enExample) | ||
| JPWO2013054872A1 (ja) | ７−［４−（４−ベンゾ［ｂ］チオフェン−４−イル−ピペラジン−１−イル）ブトキシ］−１Ｈ−キノリン−２−オン又はその塩を含む錠剤 | |
| ES2165833T1 (es) | Composicion farmaceutica revestida enterica y procedimiento de fabricacion. | |
| JP2008503475A5 (enExample) | ||
| RU2008151949A (ru) | Фармацевтические лекарственные формы и композиции фенилэфрина для абсорбции в ободочной кишке | |
| RU2012153207A (ru) | Лекарственная форма для доставки лекарственного средства в толстую кишку | |
| RU2014143536A (ru) | Фармацевтическая композиция, содержащая омелсартана медоксомил и розувастатин или его соль | |
| NZ590291A (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| JP2019509345A5 (enExample) | ||
| JP2017518985A (ja) | アリサルタン・イソプロキシル固体分散体及び医薬組成物 | |
| JP2010521437A5 (enExample) | ||
| JP2008536931A5 (enExample) | ||
| RU2014115733A (ru) | Новая соль и медицинское применение | |
| AR071706A1 (es) | Una formulacion farmaceutica de cilostazol solida de liberacion sostenida y metodo de preparacion. | |
| MX2008010879A (es) | Composiciones farmaceuticas de sodio de fluvastatina. | |
| JP2011512394A5 (enExample) | ||
| RU2008147216A (ru) | Жидкая лекарственная композиция | |
| JP2009519343A5 (enExample) | ||
| RU2007137434A (ru) | Таблетированный препарат с замедленным высвобождением для вертиго | |
| JP2017520619A5 (enExample) | ||
| JP2015533174A5 (enExample) | ||
| CY1118290T1 (el) | Φαρμακευτικες συνθεσεις δραστικων ουσιων, των οποιων παρακαμπτεται δυσκολα η οδος χορηγησης για την οποια προοριζονται |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |